A randomized trial of adding fluoxetine to a naltrexone treatment programme for heroin addicts

Addiction

Volumn 93, Issue 5, 1998, Pages 739-744

  Landabaso, M A ^a   Iraurgi, I ^b,f   Jimenez Lerma J M ^c   Sanz, J ^a   De Corres, B Fernádez ^a   Araluce, K ^d   Calle, R ^a   Gutierrez Fraile M ^e  

^a Ctro Drogodependencias de Barakaldo   (Spain)

^b Modulo Asistencia Psicosocial R   (Spain)

^c Ctro Tratamiento Toxicomanos A   (Spain)

^d Uribe Kosta Mental Health Center   (Spain)

^e UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

^f Modulo Asistencia Psicosocial R   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOXETINE; NALTREXONE;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HEROIN DEPENDENCE; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SPAIN; SURVIVAL;

EID: 0031798732     PISSN: 09652140     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1360-0443.1998.9357399.x     Document Type: Article

References (31)

1. BERGSTROM, R. F., LEMBERGER, L., FARID, N. A. & WOLEN, R. L. (1988) Clinical pharmacology and pharmacokinetics of fluoxetine; a review, British Journal of Psychiatry, 153, 47-55.
2. SELLERS, E. M., HIGGINS, G. A., TOMKINS, D. M., ROMACH, M. K. & TONEATO, T. (1991) Opportunities for treatment of Psychoactive substance use disorders with serotoninergic medications, Journal of Clinical Psychiatry, 52, 49-54.
3. AMIT, Z., SMITH, B. R. & GILL, K. (1991) Serotonin uptake inhibitors effects on motivated consummatory behaviors, Journal of Clinical Psychiatry, 52, 12, 55-60.
4. KOSTEN, T. A. & KOSTEN, T. R. (1991) Pharmacological blocking agents for treating substance abuse, Journal of Nervous and Mental Disease, 179, 583-592.
5. SCAGLIARINI, M. (1982) Consideraciones sobre el tratamiento con 5 Hidroxitriptófeno en 10 casos de toxicodependencia de heroína [Considerations on the use of 5-hydroxytryptamine in the treatment of 10 cases of heroin addiction], Informaciones Psiquiátricas, 1-2, 24-25.
6. MARSDEN, C. A. (1991) Neuropharmacology of serotonin in central nervous system, in: FEIGHMER, J. P. & BOYER, W. F. (Eds) Perspective in Psychiatry. Selective serotonin re-uptake inhibitors, pp. 11-39 (West Sussex, Wiley).
7. ARNOULD, S. F. (1995) Neuroanatonomy, in: FRAZER, A., MOLINOFF, P. & WINOKUR, A. (Eds) Biological bases of brain function and disease pp. 19-37 (New York, Lippincott-Raven).
8. AGHAJANIAN, G. K., SPROUSE, J. S. & RASMUSSEN, K. (1987) Physiology of the midbrain serotonin system, in: MELTZER, H. (Ed.) Psychopharmacology. The hard generation of progress pp. 87-106 (New York, Raven).
9. POLLACK, M. H. & ROSENBAUM, J. F. (1991) Fluoxetine treatment of cocaine abuse in heroin addicts, Journal of Clinical Psychiatry, 51, 31-33.
10. COVI, L., HESS, J. M., KREITER, N. A. & HAERTZEN, C. A. (1995) Effects of combined fluoxetine and counselling in the outpatient treatment of cocaine abusers, American Journal of Drug Alcohol Abuse, 21, 327-344.
11. GERRA, G., FERTONARI, G., ZAIMOVIC, A. et al. (1995) Hostility heroin abusers subtypes: fluoxetine and naltrexone treatment, Progress in Neuro-Psychopharmacology & Biological Psychiatry, 19, 1225-1237.
12. MAREMMANI, I., ZOLES, O., DAINNI, L., CASTRO-GIOVANNI, P. & TAGLIAMONTE, A. (1995) Fluoxetine improves outcome in addicted patients treated with opioid antagonists, American Journal on Addictions, 4, 267-271.
13. GRABOWSKI, J., RHOADES, H., ELK, R. et al. (1995) Fluoxetine is ineffective for treatment of cocaine dependence or concurrent opiate and cocaine dependence: two placebo-controlled, double-blind trials, Journal of Clinical Psychopharmacology, 15, 163-174.
14. LANDABASO, M. A., SANZ, J., AIZPURU, A. et al. (1995) Inhibidores selectivos de la recaptacion de Serotonina en adictos a opiáceos [Selective inhibitors of the uptake of serotonin in opiate addicts], Psiquiatría Biológica, 2, 166-170.
15. DEROGATIS, L. (1983) SCL-90-R Manual II (Towson, MD, Clinical Psychometric Research).
16. GONZÁLEZ, J. P. & BROGDEN, R. M. (1988) Naltrexone a review, Drugs, 35, 192-213.
17. GARCIA-ALONSO, F., GUTIÉRREZ, M., SAN, L. et al. (1989) A multicenter study to introduce naltrexona for opiate dependence in Spain, Drug and Alcohol Dependence, 23, 117-121.
18. ANTON, R. F., HOGAN, I., JALALI, B., RIORDAN, C. E. & KLEBER, H. D. (1981) Multiple family therapy and Naltrexone in the treatment of opiate dependence, Drug and Alcohol Dependence, 8, 157-168.
19. WASHTON, A. M., GOLD, M. S. & POTTASH, A. C. (1984) Successful use of naltrexone in addicted physicians and business executives, Advances in Alcohol and Substance Abuse 4, 84-96.
20. KLEBER, H. D. & KOSTEN, T. R. (1984) Naltrexone induction: psychologic and pharmacologic strategies, Journal of Clinical Psychiatry, 45, 29-38.
21. HAWKS, R. L. & CHIANG, C. N. (1986) Urine testing for drugs of abuse, Research Monograph 73. (Maryland, National Institute on Drug Abuse, Department of Health and Human Sciences).
22. OERELLICH, M. (1980) Enzyme immunoassays in clinical chemistry: present status and trends, Journal of Clinical Chemistry and Clinical Biochemistry, 18, 197-208.
23. HARRIS, E. K. & ALBERT, A. (1991) Survivorship Analysis for Clinical Studies (New York, Marcel Dekker Press).
24. IRAURGI, I., JIMÉNEZ-LERMA, J. M., HERRERA, A., MURUA, F. & GUTIERREZ-FRAILE, M. (1997) Tasas de retención y consumo en un programa de antagonistas opiáceos. Un análisis de supervivencia [Retention and lapse rates within an opiate antagonist programme. A survival analysis], Adicciones, 9, 7-21.
25. ARIÑO, J., TEJERO, J. A., PÉREZ, I., MENDIA, A. & ESTÉBANEZ, A. (1993) Evaluación de un programa de naltrexona en un servicio ambulatorio de toxicomanías [Evaluation of a naltrexone programme at a substance abuse outpatients clinic], Adicciones, 5, 53-66.
26. LÓPEZ-IBOR, J. J., PÉREZ DE LOS COBOS, J. C., OCHOA, E. & HERNÁNDEZ, M. (1990) Trata-miento de mantenimiento de la dependencia a opiáceos en una clínica de naltrexona [Maintenance treatment of opiate addiction at a naltrexone clinic], Actas Luso-Española de Neurologia y Psiquiatria, 18, 246-305.
27. GUTIÉRREZ-FRAILE, M., BALLESTEROS, J., GONZÁLEZ-OLIVEROS, R. & RUiZ-DE-APODACA, J. (1995) Retention rates in two naltrexone programmes for heroin addicts in Vitoria, Spain, European Psychiatry, 10, 183-188.
28. LANDABASO, M. A., FERNÁNDEZ-DE-CORRES, B., SANZ, J., RUiZ-DE-APODACA, J., PÉREZ, B. & GUTIÉRREZ-FRAILE, M. (1996) Estudio de la evolución (1990-1993) de adictos a opiáceos en programa de antagonistas [Study of the evolution (1990-1993) of opiate addicts on antagonist programmes], Adicciones, 8, 67-74.
29. TENNANT, F. S., RAWSON, R. A., COHEN, A. J. & MANN, A. (1984) Clinical experience with naltrexone in suburban opioid addicts, Journal of Clinical Psychiatry, 45, 42-45.
30. SCHIFANO, F. & MARRA, R. (1990) Naltrexone for heroin addiction, encouraging results from Italy, International Journal of Clinical Pharmacology Therapy and Toxicology, 28, 144-146.
31. BEDATE, J., BOBES, J., OCHOA, E. & SOLE, J. (1995) Evaluación del tratamiento de los heroinómanos con naltrexona. Estudio multicéntrico [Evaluation of the treatment of heroin-addicts with naltrexone, multi-centre study], in: CASAS, M., GUTIERREZ-FRAILE, M. & SAN, L. (Eds) Advances in Drogodependences [Avances en Drogodependencias], pp. 129-168 (Barcelona, Neurociencias).